Business Strategy
The Company has a broad commercial development strategy that exploits our competitive advantages and reflects our research and development programmes.
The strategy is designed to spread the risk within the Company and provide options during the Company’s development:
- The development of its patented technology for three-dimensional cell growth is ready to go into production and to market, and this is considered low risk;
- Its programme to design and synthesise synthetic compounds to control cell differentiation is well advanced. The characterisation of several new candidate molecules is nearing completion, and this is low-medium risk;
- Its technology for the identification and development of biomarkers to follow cell differentiation is at an earlier stage and is therefore of higher risk but is potentially of significant commercial value.
Each of these technologies has a defined market. As the field of stem cell biology continues to progress, the demand for enabling technologies, such as those under development by ReInnervate, will significantly increase and further enhance their commercial value.
Visit our Science and Technology pages to find out more about ReInnervate’s research programmes and product development.
Where appropriate, the Company will adopt a risk-sharing approach by out-licensing its technology to commercial development partners. Depending on the stage of development for a particular technology, a commercial development partner would either: license the technology directly for immediate commercial exploitation and marketing; or fund the final stages of technology development in preparation for its market offering and eventual sale. In exchange, ReInnervate would envisage negotiating up-front and milestone payments through to entry of the product onto the market, and royalties on future sales.
Early revenue streams resulting either from the direct sale of ReInnervate’s products or through licensing of its technology will be re-invested into the Company’s research and development programmes.
ReInnervate is uniquely positioned to achieve its business strategy and the following attributes provide the foundations for its success:
- A strong portfolio of innovative enabling technologies
- Experienced management and technical teams, focused on realising the commercial potential of the Company’s technologies
- A unique multi-disciplinary combination of internationally recognised biological and physical science
- Appropriate patent coverage
- A conservative development plan with realistic and achievable goals